Natera, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-05 pm EDT			5-day change	1st Jan Change
215.31 ^USD	-3.06%		-3.61%	-6.02%

Jun. 04	Natera and CytoDyn Announces Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer	CI
Jun. 03	Natera Appoints Drs. Thomas Lynch and Eric Rubin to Board of Directors	CI

Published on 05/07/2026 at 05:43 pm EDT - Modified on 05/07/2026 at 08:06 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Ladies and gentlemen, welcome to Natera's First Quarter 2026 Financial Results Conference Call.

[Operator Instructions]

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Jun. 04	Natera and CytoDyn Announces Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer	CI
Jun. 03	Natera Appoints Drs. Thomas Lynch and Eric Rubin to Board of Directors	CI
May. 29	Natera, Inc. and Diakonos Oncology Corp. Announce Collaboration for Signatera in Refractory Melanoma	CI
May. 29	Natera's Signatera Selected by Diakonos Oncology for Use in Melanoma Trial	MT
May. 28	Natera Enrolls First Patients in Study Evaluating MRD-Guided Therapy for Breast Cancer	MT
May. 28	Natera Enrolls First Patients in Signal-Er 101, A Prospective, Interventional Study Evaluating Mrd-Guided Therapy in Breast Cancer	CI
May. 26	Natera Launches Enhanced Panorama Nipt Powered by Snp-Informed Deep Sequencing Technology	CI
May. 26	Natera Upgrades Prenatal Test to Improve low Fetal Fraction Accuracy	MT
May. 21	Natera Expands Operations in Austin	MT
May. 21	Natera, Inc. Expands Operations in Austin with New Sequencing Facility and Additional Lab Space	CI
May. 20	Natera Expands Enrollment in Fetal Genetic Testing Study	MT
May. 20	Expand trial of Natera's Fetal Focus single-gene NIPT surpasses >2,000 patients enrolled	RE
May. 20	Natera Inc. Expands Enrollment In Expand Clinical Trial of Fetal Focus Single-Gene Nipt	CI
May. 15	Natera Gets FDA Approval for Bladder-Cancer Test	DJ
May. 15	Natera's Signatera CDx Approved by FDA as Companion Diagnostic in Muscle-Invasive Bladder Cancer	MT